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Prostate cancer is currently the most common cancer among men
after skin cancer in most industrialized countries (Parkin et al,
1997). Because of its poorly understood aetiology, primary
prevention is not currently feasible and therefore there is consider-
able interest in screening as a potential approach to prostate cancer
control (Schr￿der and Boyle, 1993). The only means to establish
the effect of screening is to conduct large randomized controlled
trials with both mortality and quality of life as end points (Denis 
et al, 1995). Such studies are ongoing both in Europe and North
America (Auvinen et al, 1996). In the absence of empirical results,
a debate of the issue continues, which is demonstrated by the fact
that so far the number of published reviews on the subject exceeds
the number of original reports of randomized trials (as identified
from Medline).
We report here the first-year results of the Finnish trial, which is
part of the European Randomized Study of Screening for Prostate
Cancer (ERSPC), a multi-centre randomized trial with partici-
pating centres from The Netherlands, Finland, Sweden, Belgium,
Italy, Portugal and Spain. The common core protocol includes
enrolment at ages 55—69 and use of Hybritech Tandem-E PSA
assay as the screening test with a cut-off level of 4.0 ng ml—1. The
primary end point is prostate cancer mortality, with quality of life
and cost-effectiveness as the secondary end points.
MATERIALS AND METHODS
In the Finnish trial, the subjects are identified from the central
population registry of Finland. Enrolment over 4 years with a total
study population of 80 000 men is planned. The screening interval
is 4 years and up to three screening rounds are planned. The
primary end point is mortality from prostate cancer, which will be
reported based on 10 years of follow-up from randomization.
The study population of the trial consists of men born in
1929—1944 and resident in the metropolitan areas of Helsinki and
Tampere. In the first year of the study (1996), 20 398 men born in
1929, 1933, 1937 or 1941 were randomized. The subjects were
identified from the Population Registry of Finland. The only
exclusion criterion was a previous diagnosis of prostate cancer.
Information on prostate cancer was obtained through record
linkage with the Finnish Cancer Registry. A total of 90 men were
excluded before randomization because of previously diagnosed
prostate cancer. Approximately 1% of the population (200 men of
the eligible study population) has forbidden the use of their
address information for any purposes and they were also excluded
from randomization. Each year, 8000 men, i.e. approximately one
third of the eligible population, are randomized to the screening
arm and the rest to the control arm. Of the 8000 men, men who had
died or moved out of the study area between the date of random-
ization (in early January) and date of invitation, were not invited to
participate (n = 388 in 1996). Due to an error, additional 275 men
were not invited in 1996. Men in the control group were not
contacted, but will be used as a reference group for assessment of
cancer incidence and mortality at later stages. No information
pertaining to the men in the control group was available for the
present study. A letter of invitation explaining the purpose and
procedures of the study was sent to the men in the screening arm.
The letter also included information about occurrence of prostate
cancer as well as risk factors and treatment options including their
side-effects. In addition, the men were asked to fill in a question-
naire regarding urological symptoms and their treatment, as well
as previous prostate-specific antigen (PSA) tests and family
history of prostate cancer. After obtaining written informed
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consent, a venous blood sample of 15ml was drawn in a
heparinized Vacutainer tube. After separations, serum was frozen
at — 20°C and sent to the Clinical Laboratory of the Department of
Gynaecology and Obstetrics, Helsinki University Hospital. PSA
determinations were performed using the Tandem-E assay
(Hybritech, San Diego, CA, USA).
In order to detect cancers among men with PSA concentrations
below 4.0ng ml—1 and to improve sensitivity, men with serum PSA
concentration 3.0—3.9ng ml—1 were offered a supplementary
digital rectal examination (DRE)by a urologist. Initially, 119 men
with PSA 2.0—2.9 were also offered a DRE examination, but this
was soon discontinued to avoid unnecessary examinations. If the
DRE finding was suspicious for cancer, the man was referred to a
urology clinic for diagnostic examinations.
Men with serum PSA concentration of 4.0 ngml—1 or higher, as
well as those with a suspicious DRE finding, were referred to one
of the four participating hospitals for diagnostic examinations
consisting of DRE, transrectal ultrasound (TRUS) and transrectal
Tru-cut biopsy of the prostate. Random sextant biopsies were
performed on all men, and additional directed biopsies were done
if there were suspicious lesions in DRE, TRUS or both.
If a prostate cancer was diagnosed, staging was conducted using
primarily TRUS and bone scan, but also bone X-rays, computed
tomography and magnetic resonance imaging when necessary.
Similar treatment protocols were used for screen-detected cancers
as for other patients given age, grade and stage. The treatment
options for organ-confined disease include radical prostatectomy,
radical radiotherapy or watchful waiting. Advanced disease is
treated with endocrine therapy (anti-androgen, luteinizing
hormone releasing hormone agonist, oestrogen or orchidectomy)
or watchful waiting.
The study was approved by the ethical committees in each
participating hospital.
RESULTS
The number of men randomized to the screening arm of the trial
was 7337. Of them, 5053 (69%) participated (Figure 1). The
participation rate was slightly higher in the Tampere area than in
Helsinki, and there were little differences by age (Table 1).
Of the participants, 3773 (75%) had serum PSA concentrations
below 2.0ng ml—1, 852 (17%) between 2.0 and 3.9ng ml—1, and
428 (8.5%) 4.0ng ml—1 or higher (Figure 1). The PSA concentra-
tion increased with age (Table 2).
In the initial phase of the study, 119 men with PSA between 2.0
and 2.9ng ml—1 were offered a DRE. Of them, 110 (92%) under-
went DRE and eight findings (7%) raised suspicion of cancer.
Three cancers were diagnosed, yielding a positive predictive value
of 38% and detection rate of 2.7% for DRE among men with PSA
2.0—2.9ng ml—1 (Table 3).
The 272 subjects with PSA concentrations of 3.0—3.9ng ml—1
were offered a DRE and 257 (94%) accepted. Among them, 39 men
(15%) had a DRE finding suspicious for cancer and were referred
to diagnostic examinations. Nine cancers were detected corre-
sponding to a positive predictive value of 23% and detection rate of
3.3% for DRE among men with PSA 3.0—3.9ng ml—1 (Table 3).
All 428 men with a serum PSA concentration of 4.0ng ml—1 or
higher were referred to diagnostic examinations including DRE,
TRUS and prostate biopsy. Of them, 27 did not comply, because
they were already being treated by another urologist (n= 10), had
moved from the study area (n= 3), had died (n= 2) or declined
further examinations (n= 12). Of the 401 men evaluated, 106 were
diagnosed with prostate cancer (Table 3). Hence, the positive
predictive value was 26% for PSA of 4.0ng ml—1 or higher, and
54% for PSA of 10ng ml—1 or higher. The positive predictive value
Table 1Participation rate by age and centre in the Finnish prostate cancer
screening trial
Invited Participated Participation rate (%)
Age (years)
55 2663 1798 68
59 1812 1258 69
63 1490 1045 70
67 1372 952 69 P = 0.28a
Centre
Helsinki 5509 3707 67
Tampere 1828 1346 73 P < 0.001a
Total 7337 5053 69
aStatistical significance from a Pearson c2 test.
Table 2Distribution of subjects by PSA concentration and age in the
Finnish prostate cancer screening trial
Serum PSA concentration (ng ml–1)
0–1.9 2.0–2.9 3.0–3.9 4.0–9.9 ³10 Total
N(%) N (%) N (%) N (%) N (%) N
Age (years)
55 1484 (83) 176 (10) 65 (4) 61 (3) 12 (1) 1798
59 972 (77) 138 (11) 60 (5) 70 (6) 18 (1) 1258
63 730 (70) 126 (12) 78 (7) 91 (9) 20 (2) 1045
67 587 (62) 140 (15) 69 (7) 126 (13) 30 (3) 952
Total 3773 (75) 580 (11) 272 (5) 348 (8) 80 (1) 5053
P< 0.001 from a Pearson c2 test with 12°of freedom.
Table 3Distribution of screen-detected prostate cancers by grade, age and
serum PSA concentration in the Finnish prostate cancer screening trial
Grade (WHO)
I II III
Total
N (%) N (%) N (%) N
Age (years)
55 10 (50) 10 (50) – (–) 20
59 10 (29) 21 (62) 3 (9) 34
63 12 (44) 15 (56) – (–) 27
67 17 (46) 13 (35) 7 (19) 37 P=0.041
PSA (ng/ml)
2.0–2.9 3 (100) – (–) – (–) 3
3.0–3.9 4 (44) 5 (56) – (–) 9
4.0–9.9 27 (43) 32 (51) 4 (6) 63
³10 15 (35) 22 (51) 6 (14) 43 P=0.271
Total 49 (42) 59 (50) 10 (8) 118
1Statistical significance from an exact Pearson c2 test with 6°of freedom.1212 L Määttänen et al
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of serum PSA concentration of 4.0 ng ml—1 or higher decreased
from 31% among men less than 60 years of age to 22% among
men older than 60 years (data not shown).
The detection rate attributable to PSA concentration of 
4.0 ng ml—1 or higher alone was 2.1% among study participants.
When DRE examinations among men with PSA below 4.0 ng ml—1
were also taken into account, the overall detection rate of the
screening programme was 2.3% among participants or 1.6%
among all subjects in the screening arm.
Approximately nine out of ten screen-detected tumours were
well or moderately differentiated (Table 3) and organ-confined
(Table 4). Five subjects had metastatic disease. The grade tended
to be slightly lower among younger age groups. There were no
major differences in the stage distribution by age. As expected, the
proportion of organ-confined tumours was higher among men with
PSA below 10 ng ml—1 than among men with higher PSA values.
Only preliminary information on tumour volume, pathological
staging and treatment outcomes was available at this time and
these preliminary end points will therefore be reported separately
later on.
DISCUSSION
Our results indicate that good participation rate can be obtained in
a population-based screening study of prostate cancer screening.
The positive predictive value using PSA cut-off level of 4.0 ng ml—1
is acceptable. Furthermore, the vast majority of screening-detected
cancers are well or moderately differentiated and organ confined.
The Finnish prostate cancer screening trial is population based,
i.e. we were able to define the study base and identify all subjects
in it. Compared with volunteer-based studies, the population-based
approach has the advantage of permitting estimation of effects in
the general population, i.e. screening implemented as health care
policy. This requires that the screened subjects are representative
of the population. We had a high participation rate (69%), which is
essential to fulfil this requirement. The control group was not
subject to any intervention. Thus, an informed consent was not
required. However, information on prostate cancer incidence and
mortality in the control group at the aggregate level can be
obtained through record-linkage. Prostate cancer among men from
both the screening and the control arm are treated almost exclu-
sively at the participating clinics. Hence, similar treatment for both
groups can be assured and bias from different policies or outcomes
of treatment avoided.
The results presented here are based on intermediate end points
including participation rate, positive predictive value of the test,
detection rate, and characteristics of screen-detected cancers. The
primary end points of the study are mortality from prostate cancer
and quality of life. A prerequisite for mortality reduction is that a
larger proportion of screen-detected cancers are curable than of
cancers detected otherwise. For prostate cancer, this means that
cancers should be detected and treated at organ-confined stage.
However, improved stage distribution could also result from
increased detection of indolent cancers. Therefore, improvement
of stage distribution compared with otherwise-detected cancers is
a necessary, but not sufficient proof of effectiveness of a screening
programme. In general, a screening programme cannot be evalu-
ated on the basis of intermediate end points alone. Prostate cancer
screening cannot be recommended for the general population until
there is evidence of mortality reduction, and lack of adverse
quality of life effects as well as reasonable cost-effectiveness have
been demonstrated.
The positive predictive value for PSA with cut-off level of 
4.0 ng ml—1 was 27%, which is comparable with mammography
screening (Hakama et al, 1991; United Kingdom Trial of Early
Detection of Breast Cancer Group, 1992; Kerlikowske et al, 1993).
It is possible that the positive predictive value could be further
improved by determining the free PSA concentration in addition to
the total PSA (Lilja et al, 1991; Stenman et al, 1991, 1994). The
detection rate for digital rectal examination among men with PSA
below 4.0 ng ml—1 was an order of magnitude lower than among
men with PSA levels above 4 ng ml—1, which is not very encour-
aging. In fact, the detection rate for men with PSA in the range
2.0—3.9 ng ml—1 (3.1%) was close to that of the whole study popu-
lation regardless of PSA concentration (2.3%), which suggests that
men with this PSA level do not have a materially increased risk of
prostate cancer compared with the general population. The ERSPC
trial protocol is based on total PSA concentration, but it is possible
Table 4 Distribution of screen-detected cancers by clinical stage, age and serum prostate-specific antigen (PSA) concentration, Finnish
prostate cancer screening trial
Clinical stage
T1N´M0 T2N´M0 T3–4N´M0/ T1–4N´M1 Total
N (%) N (%) N (%) N
Age (years)
55 7 (35) 11 (55) 2 (10) 20
59 13 (38) 15 (44) 6 (18) 34
63 11 (41) 14 (52) 2 (7) 27
67 13 (35) 16 (43) 8 (22) 37 P=0.781
PSA (ng/ml)
2.0–2.9 – (–) 3 (100) – (–) 3
3.0–3.9 – (–) 9 (100) – (–) 9
4.0–9.9 32 (51) 26 (41) 5 (8) 63
³10.0 12 (28) 18 (42) 13 (30) 43 P>0.0011
Total 44 (37) 56 (48) 18 (15) 118
1Statistical significance from an exact Pearson c2 test with 6° of freedom.that incorporation of free to total PSA could decrease the number
of false-positive test results and improve the specificity of the
screening protocol. This issue is being investigated.
The overall detection rate of prostate cancer during the first year
of the Finnish trial (approximately 2%) is practically identical with
previous results from studies using a similar screening algorithm
(Catalona et al, 1991). Studies with other screening modalities
combined with PSA have had higher detection rates (Mettlin et al,
1996; Schr￿der et al, 1996). Generally, lower detection rates have
been reported for subsequent screens following the first round
(Labrie et al, 1996; Smith et al, 1996).
The detection rate is higher than in mammography screening
(Day et al, 1988; Hakama et al, 1991; United Kingdom Trial of
Early Detection of Breast Cancer Group, 1992). This can be
expected given the relatively slow mean growth rate of prostate
cancer (Schmid et al, 1993; Stenman, 1997) compared with breast
cancer (Peer et al, 1993).
In our study, approximately nine out of ten screen-detected
cancers were well or moderately differentiated and organ confined.
This is comparable with other studies (Labrie et al, 1996; Mettlin
et al, 1996; Smith et al, 1996; Schr￿der et al, 1996). Screen-
detected cancers were detected substantially more frequently at a
curable stage (85% vs 34% clinically organ confined) than other
prostate cancers (Auvinen et al, 1998). Typically, a larger propor-
tion of well-differentiated, slowly growing tumours are detected in
the first (prevalence) screening round than subsequent (incidence)
screening rounds, because of length bias (Hakama, 1991). Hence,
the comparison of tumour characteristics should ideally be
conducted between cancers diagnosed in the screening arm during
the prevalence screen, those diagnosed at subsequent screening
rounds and those in the control arm. This is, however, not possible
until completion of the second screening round. Empirical results
pertaining to possible overdiagnosis due to screening will have to
wait until sufficient data from randomized trials are available.
A critical issue in prostate cancer is which cancers should be
treated. Latent prostate cancer is a common incidental finding at
autopsy and prostate surgery (Breslow et al, 1977; Potosky et al,
1990). Small, well-differentiated cancers detected in asympto-
matic men are regarded as clinically insignificant (Dugan et al,
1996). A screening programme, however, is intended to detect
cancers at a pre-clinical stage, when they are small and probably
well-differentiated. It is difficult to project tumour size and grade
if the cancers were detected later, possibly at a symptomatic stage.
Therefore, it is unclear whether similar criteria of clinical signifi-
cance can be applied to screening-detected cancers. Longitudinal
population studies of serum PSA suggest that most prostate
cancers grow at a slow, but steady rate (Schmid et al, 1993;
Stenman, 1997). A tumour with a doubling time of 2 years will
grow from 1 g to about 32 g in 10 years and to 1 kg, which is likely
to be lethal, in 20 years.
The Finnish trial is designed as a low-intensity intervention: the
cut-off level for PSA is higher and screening interval longer than
in most other studies. This approach was chosen to minimize both
costs and potential adverse effects. Low overall cost could also
mean better cost-effectiveness given that the mortality reduction
and quality of life effects are comparable with more intensive
screening regimens.
The Finnish trial is a part of the ERSPC. The target sample size
of the European study is more than 180 000 subjects. This would
be sufficient to detect an average mortality reduction of 17% at 10
years of follow-up. A joint analysis is also planned with the
European and North American studies, which provides even better
power (Auvinen et al, 1996). Non-randomized studies will not
provide information on mortality reduction, due to lack of a valid
control group. Quality of life effects are an equally important issue
and will be assessed as part of the Finnish trial.
In summary, the first results of the Finnish prostate cancer
screening trial suggest that a good participation rate can be
achieved in a population-based screening trial, the positive predic-
tive value of a PSA concentration above 4 ng ml—1 is comparable
with a positive mammography result, and the cancers detected
have characteristics associated with more favourable prognosis
compared with tumours detected otherwise.
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